Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return.
As of today, Kiniksa Pharmaceuticals International's Shareholder Yield % was 0.18%.
Kiniksa Pharmaceuticals International (NAS:KNSA) Shareholder Yield % Explanation
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."
Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.
Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.
Kiniksa Pharmaceuticals International Shareholder Yield % Related Terms
Kiniksa Pharmaceuticals International Shareholder Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kiniksa Pharmaceuticals International Shareholder Yield % Chart
KNSA vs INDV, AMRX, RGC: Shareholder Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Kiniksa Pharmaceuticals International's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kiniksa Pharmaceuticals International Shareholder Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kiniksa Pharmaceuticals International's Shareholder Yield % distribution charts can be found below:
* The bar in red indicates where Kiniksa Pharmaceuticals International's Shareholder Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
Kiniksa Pharmaceuticals International (KNSA) has a Shareholder Yield % of 0.18% as of Mar. 2026. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Kiniksa Pharmaceuticals International and its competitors. According to the industry distribution chart, Kiniksa Pharmaceuticals International ranks #505 out of 969 companies in the Drug Manufacturers industry, placing it in the top 52.1%.
Is Kiniksa Pharmaceuticals International's Shareholder Yield % too high?
Kiniksa Pharmaceuticals International's current Shareholder Yield % is 0.18%. The Drug Manufacturers industry median Shareholder Yield % is 0.34. Kiniksa Pharmaceuticals International's value of 0.18% is 47.1% below this industry median. Based on the distribution chart, Kiniksa Pharmaceuticals International ranks #505 out of 969 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Kiniksa Pharmaceuticals International has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Kiniksa Pharmaceuticals International's Shareholder Yield % compare to INDV and AMRX?
According to the Drug Manufacturers industry distribution chart, Kiniksa Pharmaceuticals International ranks #505 out of 969 companies for Shareholder Yield %. This places Kiniksa Pharmaceuticals International in the lower half of its industry. The industry median Shareholder Yield % is 0.34. Kiniksa Pharmaceuticals International's value of 0.18% is 47.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shareholder Yield % for a Drug Manufacturers company?
The median Shareholder Yield % among Drug Manufacturers companies is 0.34, based on 969 companies in the industry. Companies in the top quartile (top 25%) have a Shareholder Yield % significantly above this median, while those in the bottom quartile fall well below. However, Shareholder Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kiniksa Pharmaceuticals International's current Shareholder Yield % of 0.18% is 47.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shareholder Yield % mean?
A high Shareholder Yield % can signal that a stock is expensive relative to its fundamentals. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Kiniksa Pharmaceuticals International and its competitors. For the Drug Manufacturers industry, the median Shareholder Yield % is 0.34 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kiniksa Pharmaceuticals International's current Shareholder Yield % is 0.18%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kiniksa Pharmaceuticals International stock overvalued right now?
Based on GuruFocus' analysis, Kiniksa Pharmaceuticals International (KNSA) is currently considered Significantly Overvalued. The stock's GF Value™ is $48.15, compared to a current price of $62.88 — trading 30.6% above its estimated fair value. The current Shareholder Yield % is 0.18% and 47.1% below the Drug Manufacturers industry median of 0.34. Kiniksa Pharmaceuticals International's overall GF Score™ is 54/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shareholder Yield % calculated?
Shareholder Yield % is calculated from a company's financial statements. For Kiniksa Pharmaceuticals International (KNSA), the current Shareholder Yield % is 0.18% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kiniksa Pharmaceuticals International (KNSA) Overvalued in 2026?
Based on GuruFocus' analysis, Kiniksa Pharmaceuticals International stock appears to be overvalued.
The current stock price of $62.88 is trading 30.6% above its estimated GF Value™ of $48.15.
GuruFocus considers Kiniksa Pharmaceuticals International to be Significantly Overvalued.
Key valuation signals for KNSA:
Shareholder Yield %: 0.18%
GF Value™: $48.15 vs. price of $62.88 (30.6% above fair value)
Industry Position: 47.1% below the Drug Manufacturers median (#505 of 969)
No single metric tells the full story. See the KNSA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kiniksa Pharmaceuticals International Business Description
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
54GF Score
Get the complete analysis for KNSA
Shareholder Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KNSA has been successfully added to your 
